Clinical use of navitoclax has been limited due to thrombocytopenia, as platelets are heavily dependent on BCL-XL, but careful dosing can limit this side-effect and numerous clinical trials are investigating navitoclax as a potential combination agent for the treatment of solid cancers [98,99] (clinicaltrials.gov). Here, BCL2L1 is linked to Thrombocytopenia.